



Supplementary Figure 3. A. Comparative activity of imatinib (IM), sunitinib (SU) and regorafenib (RE) vs. untreated control (CTRL) using PG48 GIST PDX with homozygous KIT exon 11 (V559D) and exon 13 (V654A) mutations. Mice were treated with drugs for 3 days. **B.** Immunoblotting phospho-KIT quantifications are relative to the normalized average of the two controls. Total actin is a loading control.